Document is current
Any future updates will be listed below
-
Authors
Adler, Anna
Bergwik, Jesper
Padra, Médea
Papareddy, Praveen
Schmidt, Tobias
Dahlgren, Madelene
Kahn, Robin
Berglund, Ulrika Warpman
Egesten, Arne
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 1 March 2025
First Online: 14 March 2025
Declarations
:
: The use of human blood from apparently healthy volunteers was approved by the local ethical review board (no. 2015/801) and performed in accordance with the amended Declaration of Helsinki and after informed consent. All mouse experiments were approved by the Malmö-Lund Animal Care Ethics Committee (ethical permits no. M3802-19 and no. 18-20687/2023).
: Not applicable.
: The Intellectual Property Right of OXC-101 is owned by the non-profit Thomas Helleday Foundation for Medical Research (THF). UWB is a board member of the THF, have shares, and also is the CEO of Oxcia AB, commercializing the clinical use of OXC-101. THF is the sponsor for an on-going clinical phase 1 trial with OXC-101. Funding was provided by Oxcia AB for the study (AE).
